Logo image of PMCB

PHARMACYTE BIOTECH INC (PMCB) Stock Overview

NASDAQ:PMCB - US71715X2036 - Common Stock

1.03 USD
+0.02 (+1.98%)
Last: 9/11/2025, 10:48:42 AM

PMCB Key Statistics, Chart & Performance

Key Statistics
52 Week High2.42
52 Week Low0.8
Market Cap7.00M
Shares6.80M
Float6.07M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)2.98
PE0.35
Fwd PEN/A
Earnings (Next)09-15 2025-09-15
IPO09-11 2003-09-11
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


PMCB short term performance overview.The bars show the price performance of PMCB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20 -30

PMCB long term performance overview.The bars show the price performance of PMCB in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PMCB is 1.03 USD. In the past month the price increased by 20.24%. In the past year, price decreased by -46.84%.

PHARMACYTE BIOTECH INC / PMCB Daily stock chart

PMCB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.79 388.89B
AMGN AMGEN INC 12.85 150.92B
GILD GILEAD SCIENCES INC 15.04 144.44B
VRTX VERTEX PHARMACEUTICALS INC 23.22 100.85B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 61.41B
REGN REGENERON PHARMACEUTICALS 12.47 60.31B
ARGX ARGENX SE - ADR 83.13 47.16B
ONC BEONE MEDICINES LTD-ADR 5.83 39.62B
INSM INSMED INC N/A 31.04B
BNTX BIONTECH SE-ADR N/A 24.44B
NTRA NATERA INC N/A 23.60B
BIIB BIOGEN INC 9.13 21.43B

About PMCB

Company Profile

PMCB logo image PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Company Info

PHARMACYTE BIOTECH INC

3960 Howard Hughes Parkway, Suite 500

Las Vegas NEVADA US

CEO: Kenneth L. Waggoner

Employees: 2

PMCB Company Website

PMCB Investor Relations

Phone: 19175952850

PHARMACYTE BIOTECH INC / PMCB FAQ

What is the stock price of PHARMACYTE BIOTECH INC today?

The current stock price of PMCB is 1.03 USD. The price increased by 1.98% in the last trading session.


What is the ticker symbol for PHARMACYTE BIOTECH INC stock?

The exchange symbol of PHARMACYTE BIOTECH INC is PMCB and it is listed on the Nasdaq exchange.


On which exchange is PMCB stock listed?

PMCB stock is listed on the Nasdaq exchange.


What is PHARMACYTE BIOTECH INC worth?

PHARMACYTE BIOTECH INC (PMCB) has a market capitalization of 7.00M USD. This makes PMCB a Nano Cap stock.


How many employees does PHARMACYTE BIOTECH INC have?

PHARMACYTE BIOTECH INC (PMCB) currently has 2 employees.


What are the support and resistance levels for PHARMACYTE BIOTECH INC (PMCB) stock?

PHARMACYTE BIOTECH INC (PMCB) has a support level at 0.93 and a resistance level at 1.11. Check the full technical report for a detailed analysis of PMCB support and resistance levels.


Should I buy PHARMACYTE BIOTECH INC (PMCB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PHARMACYTE BIOTECH INC (PMCB) stock pay dividends?

PMCB does not pay a dividend.


When does PHARMACYTE BIOTECH INC (PMCB) report earnings?

PHARMACYTE BIOTECH INC (PMCB) will report earnings on 2025-09-15.


What is the Price/Earnings (PE) ratio of PHARMACYTE BIOTECH INC (PMCB)?

The PE ratio for PHARMACYTE BIOTECH INC (PMCB) is 0.35. This is based on the reported non-GAAP earnings per share of 2.98 and the current share price of 1.03 USD. Check the full fundamental report for a full analysis of the valuation metrics for PMCB.


What is the Short Interest ratio of PHARMACYTE BIOTECH INC (PMCB) stock?

The outstanding short interest for PHARMACYTE BIOTECH INC (PMCB) is 0.19% of its float. Check the ownership tab for more information on the PMCB short interest.


PMCB Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to PMCB. When comparing the yearly performance of all stocks, PMCB is a bad performer in the overall market: 91.01% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PMCB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PMCB. No worries on liquidiy or solvency for PMCB as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PMCB Financial Highlights

Over the last trailing twelve months PMCB reported a non-GAAP Earnings per Share(EPS) of 2.98. The EPS increased by 260.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA 39.91%
ROE 42.43%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%627.43%
Sales Q2Q%N/A
EPS 1Y (TTM)260.47%
Revenue 1Y (TTM)N/A

PMCB Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

PMCB Ownership

Ownership
Inst Owners8.36%
Ins Owners2.7%
Short Float %0.19%
Short Ratio0.19